Title : LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.

Pub. Date : 2020 Oct

PMID : 32833105






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ibrutinib-based therapy represents a recent success in managing high-risk CLL patients with 17p/TP53 deletion. ibrutinib tumor protein p53 Homo sapiens
2 In summary, the data presented establish an association between LPL deletion, resistance to ibrutinib-based therapy, and poorer overall survival in TP53-deleted CLL patients. ibrutinib tumor protein p53 Homo sapiens